Home > Publications Database > The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology. > print

001     281435
005     20251102002035.0
024 7 _ |a 10.1002/alz.70689
|2 doi
024 7 _ |a pmid:40985290
|2 pmid
024 7 _ |a 1552-5260
|2 ISSN
024 7 _ |a 1552-5279
|2 ISSN
024 7 _ |a altmetric:181658239
|2 altmetric
037 _ _ |a DZNE-2025-01120
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a McDade, Eric M
|0 0000-0002-6764-3866
|b 0
245 _ _ |a The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology.
260 _ _ |a Hoboken, NJ
|c 2025
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1761730449_30627
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Tau-derived cerebrospinal fluid (CSF) biomarkers correlate with amyloid-beta (Aβ) plaques or tau tangles in Alzheimer's disease (AD). This study assessed the effects of long-term anti-Aβ antibodies on amyloid plaques, tau tangles, and CSF tau species to determine the relationships between them.A post-hoc analysis of the DIAN-TU-001 trial (NCT01760005) examined 142 participants at risk for dominantly inherited AD randomized to solanezumab (n = 50), gantenerumab (n = 52), or placebo (n = 40). High-resolution mass spectrometry quantified CSF tau species over four years.Phosphorylated tau (p-tau) species (153, 181, 217, 231) increased early in preclinical AD but were reduced with gantenerumab-mediated Aβ plaque reduction. Nearly a decade later, MTBR-tau243 and p-tau205 increased, showing no association with Aβ reduction, aligning with tau tangle pathology progression.Initially changing soluble p-tau species track Aβ plaque reduction, while ptau205 and MTBR-243 reflect tau tangle pathology, informing different pathways of therapeutic strategies.p-tau217 and p-tau231 correlate with Aβ-PET and respond to Aβ-plaque lowering therapies. Aβ immunotherapy trials support a direct link between p-tau changes and Aβ plaques Gantenerumab reduces Aβ plaques but does not affect tau NFT-related biomarkers. Blood-based p-tau217 assays may provide a non-invasive tool to monitor Aβ therapies. MTBR-tau243 strongly correlates with tau PET and tracks NFT pathology progression. Further studies are needed to validate tau biomarkers for tracking NFT-targeting therapies.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a amyloid beta plaque reduction
|2 Other
650 _ 7 |a dominantly inherited Alzheimer's disease
|2 Other
650 _ 7 |a microtubule‐binding region
|2 Other
650 _ 7 |a phosphorylated tau
|2 Other
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 7 |a Antibodies, Monoclonal, Humanized
|2 NLM Chemicals
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 7 |a gantenerumab
|0 4DF060P933
|2 NLM Chemicals
650 _ 7 |a solanezumab
|0 5D6PWO0333
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a tau Proteins: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Alzheimer Disease: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Alzheimer Disease: pathology
|2 MeSH
650 _ 2 |a Alzheimer Disease: drug therapy
|2 MeSH
650 _ 2 |a Plaque, Amyloid: pathology
|2 MeSH
650 _ 2 |a Plaque, Amyloid: drug therapy
|2 MeSH
650 _ 2 |a Plaque, Amyloid: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Antibodies, Monoclonal, Humanized: therapeutic use
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Biomarkers: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides
|2 MeSH
650 _ 2 |a Phosphorylation
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
700 1 _ |a Barthélemy, Nicolas R
|b 1
700 1 _ |a Wang, Guoqiao
|b 2
700 1 _ |a Li, Yan
|b 3
700 1 _ |a Cao, Yuchen
|b 4
700 1 _ |a Gordon, Brian
|b 5
700 1 _ |a Benzinger, Tammie L S
|b 6
700 1 _ |a Clifford, David
|b 7
700 1 _ |a Goate, Alison M
|b 8
700 1 _ |a Renton, Alan E
|b 9
700 1 _ |a Hassenstab, Jason
|b 10
700 1 _ |a Llibre-Guerra, Jorge J
|b 11
700 1 _ |a Perrin, Richard J
|b 12
700 1 _ |a Xiong, Chengjie
|b 13
700 1 _ |a Cruchaga, Carlos
|b 14
700 1 _ |a Mummery, Catherine J
|b 15
700 1 _ |a Berman, Sarah B
|b 16
700 1 _ |a Lah, James
|b 17
700 1 _ |a Roberson, Erik D
|b 18
700 1 _ |a Van Dyck, Christopher
|b 19
700 1 _ |a Gauthier, Serge
|b 20
700 1 _ |a Masters, Colin L
|b 21
700 1 _ |a Masellis, Mario
|b 22
700 1 _ |a Bittner, Tobias
|b 23
700 1 _ |a Yaari, Roy
|b 24
700 1 _ |a Chhatwal, Jasmeer
|b 25
700 1 _ |a Chrem, Patricio
|b 26
700 1 _ |a Brooks, William
|b 27
700 1 _ |a Suzuki, Kazushi
|b 28
700 1 _ |a Levin, Johannes J
|0 P:(DE-2719)2811659
|b 29
|u dzne
700 1 _ |a Jucker, Mathias
|0 P:(DE-2719)2000010
|b 30
|u dzne
700 1 _ |a Ringman, John
|b 31
700 1 _ |a Wallon, David
|b 32
700 1 _ |a Ikeuchi, Takeshi
|b 33
700 1 _ |a Lee, Jae-Hong
|0 P:(DE-HGF)0
|b 34
700 1 _ |a Roh, Jee Hoon
|b 35
700 1 _ |a Schofield, Peter
|b 36
700 1 _ |a Fox, Nick C
|b 37
700 1 _ |a Ryan, Natalie S
|b 38
700 1 _ |a Vöglein, Jonathan
|0 P:(DE-2719)2811820
|b 39
|u dzne
700 1 _ |a Karch, Celeste
|b 40
700 1 _ |a Ibáñez, Laura
|b 41
700 1 _ |a Day, Gregory S
|b 42
700 1 _ |a Sánchez-Valle, Raquel
|b 43
700 1 _ |a Daniels, Alisha
|b 44
700 1 _ |a Morris, John C
|b 45
700 1 _ |a Supnet-Bell, Charlene
|b 46
700 1 _ |a Levey, Allan I
|b 47
700 1 _ |a Bateman, Randall J
|0 0000-0002-7729-1702
|b 48
700 1 _ |a Team, DIAN-TU Study
|b 49
700 1 _ |a Team, DIAN Obs
|b 50
|e Collaboration Author
773 _ _ |a 10.1002/alz.70689
|g Vol. 21, no. 9, p. e70689
|0 PERI:(DE-600)2201940-6
|n 9
|p e70689
|t Alzheimer's and dementia
|v 21
|y 2025
|x 1552-5260
856 4 _ |u https://pub.dzne.de/record/281435/files/DZNE-2025-01120%20SUP.pdf
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/281435/files/DZNE-2025-01120.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/281435/files/DZNE-2025-01120.pdf?subformat=pdfa
856 4 _ |u https://pub.dzne.de/record/281435/files/DZNE-2025-01120%20SUP.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:pub.dzne.de:281435
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 29
|6 P:(DE-2719)2811659
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 30
|6 P:(DE-2719)2000010
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 39
|6 P:(DE-2719)2811820
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 1
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-06
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0
|0 LIC:(DE-HGF)CCBYNC4
|2 HGFVOC
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-01-06
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-06
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-06
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-06
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 0
920 1 _ |0 I:(DE-2719)1111016
|k AG Levin
|l Clinical Neurodegeneration
|x 1
920 1 _ |0 I:(DE-2719)1210001
|k AG Jucker
|l Cell Biology of Neurological Diseases
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)1111016
980 _ _ |a I:(DE-2719)1210001
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21